CN106632605B - Active peptide prepared from tuna leftovers and having liver injury repair effect - Google Patents
Active peptide prepared from tuna leftovers and having liver injury repair effect Download PDFInfo
- Publication number
- CN106632605B CN106632605B CN201611201846.7A CN201611201846A CN106632605B CN 106632605 B CN106632605 B CN 106632605B CN 201611201846 A CN201611201846 A CN 201611201846A CN 106632605 B CN106632605 B CN 106632605B
- Authority
- CN
- China
- Prior art keywords
- tuna
- asp
- liver
- cells
- leftovers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000021190 leftovers Nutrition 0.000 title claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 15
- 230000000694 effects Effects 0.000 title claims abstract description 10
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 9
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 8
- 230000008439 repair process Effects 0.000 title description 3
- 230000000975 bioactive effect Effects 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000000047 product Substances 0.000 abstract description 25
- 210000005229 liver cell Anatomy 0.000 abstract description 10
- 238000012545 processing Methods 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 239000006227 byproduct Substances 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 21
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 108091005658 Basic proteases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 238000010266 Sephadex chromatography Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 238000013232 NAFLD rodent model Methods 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000003578 marine toxin Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- PXLNPFOJZQMXAT-BYULHYEWSA-N Asp-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O PXLNPFOJZQMXAT-BYULHYEWSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- KZKVVWBOGDKHKE-QTKMDUPCSA-N Met-Thr-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 KZKVVWBOGDKHKE-QTKMDUPCSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a bioactive peptide with liver injury repairing function prepared by tuna leftovers, which has the amino acid sequence as follows: Met-Thr-His-Asp-Asp-Val-Asp-Glu. The method takes the leftover of the tuna which is a byproduct of aquatic product processing as a raw material, extracts the collagen peptide with the liver cell repairing effect from the raw material, is simple and easy to implement, has low production cost, can obviously improve the value of the aquatic product processing byproduct, avoids waste, protects the environment and provides an early basis for developing related functional foods.
Description
Technical Field
The invention relates to an active peptide, in particular to an active peptide with a liver injury repairing effect, which is prepared by using tuna leftovers.
Background
The ocean area accounts for about 71 percent of the earth surface, the organisms living in the ocean are up to 20 thousands, and the unique living environment and living mode of the marine organisms determine the complexity, diversity and particularity of marine products, so that the extraction and separation of effective bioactive substances from the marine organisms have important significance, and the extraction of effective bioactive substances from marine plants, marine animals and marine microorganisms is more and more concerned by experts and scholars. At present, the most studied are marine biotoxins, anti-tumor factors, anti-oxidation factors, cardiovascular active peptides and the like. The life of human beings is deeply influenced by marine toxins, wherein toxic organisms still threaten the marine life and production of people, and the marine toxins which are found comprise tetrodotoxin, stinging tail toxin, jellyfish toxin, saxitoxin and the like. The marine biotoxin can be directly developed into a natural medicine or further used as a lead compound for the design of innovative medicines. With the rapid development of tuna fishery in China, tuna processing has become the central importance of economic development of ocean fishery. Tuna products are mainly processed into cans, and the produced leftovers account for 50-70% of the total weight. Mainly takes viscera, minced meat and fish heads as main materials, and leftovers not only contain high-quality protein, but also are rich in a large amount of bioactive substances. However, the existing tuna leftovers are simply utilized and are relatively wasted.
Non-alcoholic fatty liver disease is a pathological syndrome unrelated to alcohol, and is mainly characterized by fat accumulation and steatosis in liver cells, NAFLD can develop into non-alcoholic steatohepatitis, and finally, the liver cirrhosis and liver cancer can be possibly degraded. The incidence of the NAFLD is high in developed countries, the incidence of the NAFLD is up to 20% -30%, the incidence of the NAFLD of adults in developed regions of China is about 15%, the life of people is seriously threatened, but the incidence of the NAFLD is low in laggard regions of China. In recent years, with the improvement of the living standard of Chinese people, the aging of population and the prevalence of obesity, and the gradual increase of fat and grease ingested by people, NAFLD patients gradually increase in China in recent years and become the most common liver diseases affecting the body health of people.
With respect to the pathogenesis of NAFLD, it is most accepted by the "secondary stroke" theory proposed by Day that the accumulation of lipids in hepatocytes constitutes the first stroke, which is the oxidative stress and lipid peroxidation that occurs on this basis. The occurrence of NAFLD includes insulin and leptin resistance, excessive accumulation of fat in the liver, inflammatory reactions in liver tissue and cells, and the like. The primary function of insulin is to reduce blood glucose levels by up-regulating the concentration of glucose transporters to facilitate glucose absorption. When cells metabolize, glucose taken in by the body is converted into hepatic glycogen to be stored in the liver, the other action of insulin can store lipid and inhibit lipolysis, and intracellular insulin resistance can hydrolyze stored triglyceride to increase the content of free fatty acid in plasma, so that the accumulation of fat in the liver cells is caused.
The harm of NAFLD mainly includes the following aspects: the traditional Chinese medicine composition can promote atherosclerosis, so patients are often accompanied with hyperlipidemia, the blood viscosity of the patients is increased, and due to the small molecular weight of low-density lipoprotein, the low-density lipoprotein easily causes arteries deposited on blood vessel walls, so that the elasticity of the arteries is reduced, the flexibility of the arteries is reduced, blood circulation disorder is finally caused, and the life is threatened; NAFLD also induces hypertension and coronary heart disease, and is very likely to cause myocardial infarction and death; NAFLD also impairs digestion, and proteins, carbohydrates and lipids ingested by the body must be metabolized by the liver, but the liver of patients with NAFLD is injured and tends to involve the digestive system. NAFLD can exacerbate liver damage. Accumulation of fat in the liver. The liver cells are enlarged and denatured, the cell nucleus is extruded to one side, and the burden of mitochondria can be further increased, so that the metabolism of other nutrients, vitamins and hormones is influenced. Long-term hepatocyte degeneration accelerates damage to hepatocytes, which may further progress to liver fibrosis and even liver cancer, and NAFLD may induce or exacerbate diabetes.
At present, no effective treatment method for NAFLD exists, non-basic treatment methods such as drug treatment and surgical treatment are mostly adopted, and the non-basic treatment mainly comprises treatment for improving insulin resistance, treatment for NAFLD-related basic diseases and metabolic syndrome, anti-oxidation and anti-inflammation and liver protection treatment, weight-losing surgical treatment and the like. Research has proved that biguanides and thiazolidines can significantly improve collective insulin resistance, but the side effects present therein are not of great concern. The treatment of NAFLD-related basic diseases and metabolic symptoms mainly includes weight loss treatment, lipid lowering treatment and angiotensin converting enzyme inhibitor treatment. The fat-reducing exercise including diet exercise and aerobic exercise can reduce the fat content in the body to a certain extent, thereby relieving the body pressure and achieving the effect of relieving. Lipid lowering therapy has the same principle as weight reducing therapy, but the effect and safety of lipid lowering drugs are yet to be studied.
Disclosure of Invention
The invention aims to provide the active peptide with the liver injury repairing function prepared by utilizing the tuna leftovers, which is prepared by taking the tuna leftovers which are aquatic product processing byproducts as raw materials and extracting the collagen peptide with the liver cell repairing function from the raw materials, is simple and easy to implement, has low production cost, can obviously improve the value of the aquatic product processing byproducts, avoids waste, protects the environment and also provides an early basis for developing related functional foods.
The technical scheme adopted by the invention for solving the technical problems is as follows:
an active peptide with liver injury repairing effect prepared from tuna leftovers has an amino acid sequence as follows: Met-Thr-His-Asp-Asp-Val-Asp-Glu (SEQ ID No. 1).
Preferably, the preparation method comprises the following steps:
(1) pretreatment of tuna leftovers: cleaning the fish meat part of the leftovers of the fresh tuna, and then homogenizing to obtain meat pulp;
(2) and (3) carrying out enzymolysis reaction: mixing the meat pulp obtained in the step (1) with water according to a feed-liquid ratio of 1g:3mL, and then adding alkaline protease for enzymolysis reaction;
(3) and (3) ultrafiltration: after the enzymolysis reaction in the step (2) is finished, inactivating enzyme, centrifuging, collecting supernatant, ultrafiltering the supernatant by using an ultrafiltration membrane, respectively intercepting molecular segment products with three molecular weights, freeze-drying, respectively acting the molecular segment products with the three molecular weights on model group cells at the drug concentration of 10mg/mL, and screening out components capable of reducing the content of TG in the cells to the maximum;
(4) sephadex G-25 chromatographic separation: taking 100mg of the component which is obtained in the step (3) and can reduce the content of TG in cells to the maximum, adding distilled water to prepare 2mL of solution, centrifuging, taking supernatant, filtering through a 0.22 mu m filter membrane, passing filtrate through a Sephadex G-25 column for chromatographic separation, taking distilled water as eluent, and carrying out balanced elution on the gel column; regulating the flow rate of a constant flow pump to be 1.1mL/min, collecting each tube for 3.5min, detecting the absorbance of each tube at 280nm, collecting the eluent of each peak, and freeze-drying after rotary evaporation; each peak product is respectively prepared into 10mg/mL medicine concentration to act on model group cells, and the peak product which enables the content reduction rate of TG in the cells to be the maximum is selected as the target peptide.
Preferably, the enzymolysis conditions in step (2) are as follows: the dosage of the alkaline protease is 1000U per g of meat pulp, the enzymolysis temperature is 50 ℃, the pH value is 10, and the time is 6 h.
Preferably, the three molecular weights in step (3) are specified below: the molecular weight is less than 5kDa, the molecular weight is 5kDa-8kDa, and the molecular weight is more than 8 kDa.
The invention has the beneficial effects that: the method has the advantages of simple and easy operation and low production cost, can obviously improve the value of aquatic product processing byproducts, avoids waste, protects the environment and also provides early basis for developing related functional foods.
Drawings
FIG. 1 is a graph showing the results of G-25 Sephadex chromatography performed on < 5kDa enzymatic hydrolysate of the present invention.
Detailed Description
The technical solution of the present invention will be further specifically described below by way of specific examples.
In the present invention, the raw materials and equipment used are commercially available or commonly used in the art, unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified.
Tuna offal was purchased from Zhongshan Jia Zhejiang and Jia food processing, Inc.; normal human hepatocytes: zhang's hepatocytes (Chang Liver cells) were purchased from the cell center of Xiangya medical college, school of Hunan university, and subcultured in this laboratory.
Model group cells: selecting Chang Liver cells in good growth state, inducing the Chang Liver cells by using 15 mu g/mL palmitic acid, collecting the cells after inducing for 12h, 24h, 48h and 72h respectively, and determining the content of TG, wherein the TG detection method is carried out according to the kit instructions. And selecting the induction time which obviously increases the TG content in the Chang lever cell and ensures that the cell grows well, and establishing an in vitro NAFLD cell model.
Example (b):
1. method of producing a composite material
1.1 pretreatment of tuna offcuts
Taking the fish meat part of the fresh tuna leftovers, slightly stirring the fish meat part in distilled water, washing off impurities, homogenizing the mixture, and storing the homogenate at the temperature of minus 20 ℃ for later use.
1.2 screening of the optimal enzyme species for tuna leftover enzymolysis
Alkaline protease, pepsin, neutral protease, trypsin and papain are adopted, the optimum temperature and the optimum pH are respectively selected, the enzymolysis time is 6 hours, the enzyme adding amount is 1000U/g, the homogenate of the tuna leftovers is subjected to enzymolysis, and the enzymolysis conditions are shown in table 1. Inactivating enzyme at 100 deg.C for 10min after enzymolysis, freeze drying, allowing the dried product to act on model group cells at concentration of 10mg/mL for 24h, and screening protease with maximum TG content reduction rate. The calculation method of the TG content reduction rate is as follows: the TG content reduction rate (%) (model group TG content-drug group TG content)/model group TG content × 100%.
TABLE 1 enzymatic conditions for different proteases
1.3, separation and purification of tuna leftover enzymatic hydrolysis oligopeptide
Ultrafiltering the enzymolysis product obtained under the optimal enzymolysis condition, respectively intercepting molecular segment products less than 5kDa, 5kDa-8kDa and more than 8kDa, freeze-drying, and standing at-20 deg.C for use. The product of the above components was allowed to act on the cells of the model group at a drug concentration of 10mg/mL, and the components capable of reducing the intracellular TG content most were selected.
1.4 Sephadex G-25 chromatography separation
Preparing 100mg of the components (freeze-dried products) which are screened out in the step 1.3 and can reduce the content of TG in cells to the maximum into 2mL of solution, centrifuging, taking supernatant, filtering the supernatant through a 0.22 mu m filter membrane, carrying out chromatographic separation on the filtrate through a Sephadex G-25 column, taking distilled water as eluent, and carrying out balanced elution on the gel column; regulating the flow rate of a constant flow pump to be 1.1mL/min, collecting each tube for 3.5min, detecting the absorbance of each tube at 280nm, collecting the eluent of each peak, performing rotary evaporation, and performing freeze drying. The drug concentration of 10mg/mL is prepared to act on model group cells, and peak components which enable the content reduction rate of TG in the cells to be the maximum are screened.
1.5 determination of hepatocyte function index
Respectively measuring the contents of indexes such as ALT, AST, MDA, GSH-ST, gamma-GT, SOD and the like in cells of the normal group, the model group and the 10mg/mL and 20mg/mL drug group Chang lever, and carrying out the detection method according to the kit instructions.
2 analysis of results
2.1 screening results of the optimal conditions for the enzymatic hydrolysis of tuna offcuts
The product was collected by subjecting tuna leftover homogenate to enzymatic hydrolysis using 5 proteases, and the intracellular TG content was measured 24h after treatment of model group cells, the results are shown in Table 2. From Table 2, it can be concluded that the alkaline protease substrate maximizes the reduction of TG content in the cells (P <0.05), and thus the alkaline protease is selected as the optimum enzyme species.
Table 2 variation of TG content in different protease cleavage products versus NAFLD cell model: (n=6)
Note:#compared with the model group, P is less than 0.05.
2.2 preliminary separation result of oligopeptide from tuna offcuts
Ultrafiltering tuna leftover enzymolysis liquid obtained by alkaline protease under the optimal enzymolysis condition to obtain 3 different molecular segment products of less than 5kDa, 5kDa-8kDa and more than 8kDa, and acting on model group cells for 24h, wherein the TG content detection result is shown in Table 3. As can be seen from Table 3, the < 5kDa molecular fragment maximizes the reduction in TG content in the cells of the model group from 36.12. mu. mol/G to 14.29. mu. mol/G (P <0.05) of the model group, and therefore the enzymatic hydrolysate of the < 5kDa molecular fragment was selected for G-25 Sephadex chromatography.
TABLE 3 variation of protease enzymatic products of different molecular weight segments on TG content in NAFLD model cells: (n=6)
Note: p <0.05 compared to model group.
2.3 Sephadex G-25 chromatographic separation result
G-25 sephadex chromatography is carried out on the < 5kDa enzymolysis solution, and the eluates of all tubes are collected to measure the absorbance of the solution at the wavelength of 280nm, so that 4 peaks, namely a peak I, a peak II, a peak III and a peak IV, are obtained as shown in figure 1. The four peak products were lyophilized and the dried products were applied to the model group cells at a concentration of 10mg/mL, and as a result, as shown in Table 4, the peak I product resulted in the greatest decrease in TG content of the model group, with a decrease rate of 64.89%.
Note: p <0.05 compared to model group.
2.4 determination result of oligopeptide sequence of tuna offal
The amino acid sequence of the target peptide of the peak I product is detected as follows: Met-Thr-His-Asp-Asp-Val-Asp-Glu, ESI/MS molecular weight 960.10 Da.
2.5 measurement results of hepatocyte function index
The result of detecting the liver cell function index is shown in Table 5, and it can be seen that the content model group of MDA, GSH-ST, ALT, AST and gamma-GT is obviously higher than the normal group, and the level of the drug group after the action of the active peptide of the invention is obviously reduced (P is less than 0.05). The SOD content is higher in normal group cells, is reduced in a model group, and is increased in a drug group level (P < 0.05).
Note: comparison with normal group, P<0.05;#Comparison with model groups, P<0.05。
The above-described embodiments are only preferred embodiments of the present invention, and are not intended to limit the present invention in any way, and other variations and modifications may be made without departing from the spirit of the invention as set forth in the claims.
SEQUENCE LISTING
<110> Zhejiang ocean university
<120> active peptide with liver injury repair effect prepared by tuna leftovers
<130>2016.12
<160>1
<170>PatentIn version 3.3
<210>1
<211>8
<212>PRT
<213> tuna
<400>1
Met Thr His Asp Asp Val Asp Glu
1 5
Claims (1)
1. A bioactive peptide with liver injury repairing effect prepared from tuna leftovers is characterized in that the amino acid sequence is as follows: Met-Thr-His-Asp-Asp-Val-Asp-Glu.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611201846.7A CN106632605B (en) | 2016-12-22 | 2016-12-22 | Active peptide prepared from tuna leftovers and having liver injury repair effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611201846.7A CN106632605B (en) | 2016-12-22 | 2016-12-22 | Active peptide prepared from tuna leftovers and having liver injury repair effect |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106632605A CN106632605A (en) | 2017-05-10 |
CN106632605B true CN106632605B (en) | 2020-06-16 |
Family
ID=58827157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611201846.7A Active CN106632605B (en) | 2016-12-22 | 2016-12-22 | Active peptide prepared from tuna leftovers and having liver injury repair effect |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106632605B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
CN111295187A (en) * | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | Amino acid composition for treating liver diseases |
CN108610413A (en) * | 2018-04-23 | 2018-10-02 | 浙江海洋大学 | A kind of safe and comfortable collagen peptide to hepatic injury with repair |
CN108341864A (en) * | 2018-04-23 | 2018-07-31 | 浙江海洋大学 | A kind of preparation method to anglerfish skin collagen peptide of the hepatic injury with repair |
CN108315378A (en) * | 2018-04-23 | 2018-07-24 | 浙江海洋大学 | A kind of preparation method to Ruditapes philippinarum polypeptide of the hepatic injury with repair |
CN112839643A (en) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | Compositions and methods for treating fat infiltration in muscle |
CN118234705A (en) * | 2021-11-12 | 2024-06-21 | 深圳利沃生物医药科技有限公司 | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases |
CN113999288B (en) * | 2021-12-14 | 2023-06-23 | 山东省海洋科学研究院(青岛国家海洋科学研究中心) | Polypeptide with proliferation promoting function prepared from fish leftovers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102808010A (en) * | 2011-05-30 | 2012-12-05 | 浙江海洋学院 | Method for preparing antihypertensive peptides through enzymolysis of ground meat proteins of tuna |
KR20130141877A (en) * | 2012-06-18 | 2013-12-27 | 주식회사 마크로케어 | Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same |
CN105624247A (en) * | 2016-02-29 | 2016-06-01 | 浙江海洋学院 | Preparation method for activator of Nrf2-ARE pathway in tuna high F ratio oligopeptide |
-
2016
- 2016-12-22 CN CN201611201846.7A patent/CN106632605B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102808010A (en) * | 2011-05-30 | 2012-12-05 | 浙江海洋学院 | Method for preparing antihypertensive peptides through enzymolysis of ground meat proteins of tuna |
KR20130141877A (en) * | 2012-06-18 | 2013-12-27 | 주식회사 마크로케어 | Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same |
CN105624247A (en) * | 2016-02-29 | 2016-06-01 | 浙江海洋学院 | Preparation method for activator of Nrf2-ARE pathway in tuna high F ratio oligopeptide |
Also Published As
Publication number | Publication date |
---|---|
CN106632605A (en) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106632605B (en) | Active peptide prepared from tuna leftovers and having liver injury repair effect | |
CN107141336B (en) | Yak bone protein peptide with DPP-IV inhibitory activity and preparation method thereof | |
Wong et al. | Influence of drying treatment on three Sargassum species | |
Pratama et al. | Proximate analysis, amino acid profile and albumin concentration of various weights of Giant Snakehead (Channa micropeltes) from Kapuas Hulu, West Kalimantan, Indonesia | |
CN111494495A (en) | Application of litchi pulp dietary fiber-bonded phenol adduct in preparation of preparation for improving intestinal microecology | |
CN103393191A (en) | Crocodile meat oral liquid and preparation method thereof | |
Liu et al. | Hydrolyzed peptides from purple perilla (Perilla frutescens L. Britt.) seeds improve muscle synthesis and exercise performance in mice | |
Shi et al. | Glycation sites and bioactivity of lactose-glycated caseinate hydrolysate in lipopolysaccharide-injured IEC-6 cells | |
KR102136886B1 (en) | Composition for prevention and treatment of muscular disorders or improvement of muscular functions comprising functional fermented material using oyster | |
CN103099248A (en) | Method for preparing oyster active component | |
Yamanushi et al. | Antihypertensive effects of abalone viscera fermented with Lactiplantibacillus pentosus SN001 via angiotensin-converting enzyme inhibition | |
CN113637717A (en) | Andrias davidianus oligopeptide and preparation method and application thereof | |
CN117820437B (en) | Jerusalem artichoke peptide, preparation method thereof and application thereof in kidney-protecting auxiliary diabetes treatment antioxidant product | |
JP2006271377A (en) | Enzymolysis product of animal liver and food containing the same | |
CN114989258B (en) | Application of plant extract composition in preparing product for treating constipation and reducing weight | |
CN113768028B (en) | Method for separating protein from black powder sorghum and application thereof | |
KR101887764B1 (en) | Process for Extracting of red bean shell having anti obesity and Compositions comprising the Extracts as an active ingredient | |
CN104938853B (en) | A kind of preparation and its application of quality broiler chicken additive | |
CN106173853B (en) | Nutritional composition for reducing blood fat and application thereof | |
CN116751247A (en) | Tuna heart arteria artery bulb antioxidant peptide with liver protection effect, and preparation method and application thereof | |
CN111944009B (en) | Preparation method and application of salicornia bigelovii antihypertensive peptide | |
Saneyasu et al. | The extract of soybean protein increases slow-myosin heavy chain expression in C2C12 myotubes | |
CN108893512B (en) | Bee pupa protein peptide with DPP-IV inhibition and anti-fatigue functions and preparation method thereof | |
KR20140066317A (en) | Food for improving liver function comprising black rice culture of lentinus edodes mycelia adding hovenia dulcis extract as effective component | |
KR101757070B1 (en) | Food composition for enhancing the muscle endurance comprising the extract of cyprinus carpio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |